Search results
FDA grants approval for two Eylea biosimilars for eye conditions
Pharmaceutical Technology via Yahoo Finance· 1 day agoYesafili is a trademark of Biosimilars Newco, a Biocon Biologics company. Opuviz is a trademark of...
Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili™. Enters U.S....
WTRF Wheeling· 1 day agoBiocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and Drug Administration ...
Biocon Biologics gets US FDA nod for biosimilar version of eye treatment drug Eylea
Investing.com· 1 day agoBiocon Biologics gets US FDA nod for biosimilar version of eye treatment drug Eylea
Foundation Fighting Blindness Awards Inaugural Grants in PRPH2 and Associated Retinal Diseases...
WKRN Nashville· 3 hours agoThe Foundation Fighting Blindness, the driving force in the global development of treatments and cures for blinding diseases, has announced the recipients of the first awards ...
6 Everyday Habits That You Didn't Know Are Ruining Your Vision
CNET· 23 hours agoIf you've never experienced any issues with your vision or your eye health for that matter, then you...
Astaxanthin Is the Deep Sea Supplement Experts Say Improves Longevity + Benefits Heart and Vision
First for Women via Yahoo News· 1 day agoIf you’d prefer a naturally-sourced supplement (which Dr. Shimek recommends), try Micro Ingredients...
Foundation Fighting Blindness to Host VISIONS 2024 Conference
WFRV 5 Green Bay· 5 days ago...PRNewswire/ -- The Foundation Fighting Blindness, the driving force in the global development of treatments and cures for blinding diseases, will host its VISIONS 2024 conference at the Chicago Marriott Downtown...diseases such as retinitis pigmentosa, Usher syndrome, Stargardt disease, Leber...
FDA approves 2 Eylea biosimilars
Becker’s Hospital Review· 2 days agoThe FDA granted approval to Biocon Biologics' drug Yesafili and Samsung Bioepis and Biogen's drug Opuviz, the agency announced May 20. The two drugs are biosimilars for Eylea, an injection made ...
Ocugen completes second cohort dosing in Stargardt trial By Investing.com
Investing.com· 7 days agoThe trial represents a potential breakthrough for patients with this inherited retinal disease,...
Prevent Blindness Offers New Resources for Education and to Raise Awareness for Stargardt Disease
PRWeb· 1 day agoCHICAGO, May 21, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading nonprofit eye health and safety organization, has created new educational materials on Stargardt disease, ...
